QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.097972v1 317/2/480    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Neff, N. H. Articles by Hadjiconstantinou, M. Search for Related Content PubMed PubMed Citation Articles by Neff, N. H. Articles by Hadjiconstantinou, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE CLOZAPINE

NEUROPHARMACOLOGY

Clozapine Modulates Aromatic L-Amino Acid Decarboxylase Activity in Mouse Striatum

Departments of Pharmacology (N.H.N.) and Psychiatry, Division of Molecular Neuropsychopharmacology (T.A.W., A.-M.D., M.H.), Ohio State University College of Medicine and Public Health, Columbus, Ohio

Clozapine is efficacious for treating dopaminergic psychosis in Parkinson's disease and ameliorates L-DOPA-induced motor complications. Based on its pharmacology and reported enhancing effects on dopamine metabolism and tyrosine hydroxylase activity, we investigated whether it could modulate the activity of aromatic L-amino acid decarboxylase (AAAD), the second enzyme for the biosynthesis of catecholamines and indoleamines. A single dose of clozapine increased AAAD activity of striatum in a dose- and time-dependent manner. At 1 h, enhanced enzyme activity was characterized by an increased V_max for substrate and cofactor and was accompanied by elevated levels of protein in striatum and mRNA in substantia nigra, ventral tegmental area, locus coeruleus, and raphe nuclei. Acute clozapine increased tyrosine hydroxylase activity in striatum but with differing temporal patterns from AAAD and heightened dopamine metabolism. Interestingly, the response of the dopaminergic markers to clozapine was greater following a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesion. Chronically administered clozapine increased AAAD activity and protein and dopamine metabolism in striatum without affecting tyrosine hydroxylase. Exogenous L-DOPA decarboxylation was accelerated in the striatum of intact and MPTP-lesioned mice following acute clozapine, and the effect was exaggerated in the MPTP mice. To identify receptors involved, antagonists of receptors occupied by clozapine were employed. D4, 5-HT1_A, and 5-HT2_A, in addition to D1, D2, and D3, antagonists, augmented AAAD activity in striatum, whereas 5-HT2_C, 5-HT3, muscarinic, and -1 and -2 adrenergic antagonists were ineffective. For the first time, these studies provide evidence that clozapine modulates AAAD activity in the brain and suggests that dopamine and serotonin receptors are involved.

Address correspondence to: Dr. Norton H. Neff, Department of Pharmacology, Ohio State University College of Medicine and Public Health, Graves Hall, Room 5067, 333 West 10th Avenue, Columbus, OH 43210. E-mail: neff.2{at}osu.edu